Basic Information
Doptelet
Regulatory Information
EMEA/H/C/004722
June 20, 2019
April 26, 2019
9
November 22, 2024
Company Information
Sweden
SE-112 76 Stockholm
Swedish Orphan Biovitrum AB (Publ)
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Overview Summary
Doptelet is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding. The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body). Doptelet contains the active substance avatrombopag.